| Heather Waselchalk, | |
|
200 Elizabeth St, Charleston, WV 25311-2119 | |
| (304) 348-7740 | |
| Not Available |
| Full Name | Heather Waselchalk |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 200 Elizabeth St, Charleston, West Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699102061 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | W2E112800347 (West Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Heather Waselchalk, 501 22nd St, Dunbar, WV 25064-1711 Ph: () - | Heather Waselchalk, 200 Elizabeth St, Charleston, WV 25311-2119 Ph: (304) 348-7740 |
News Archive
Sydney researchers have discovered a new type of immune cell in skin that plays a role in fighting off parasitic invaders such as ticks, mites, and worms, and could be linked to eczema and allergic skin diseases.
Viruses can travel around cells they infect by hitching a ride on a microscopic transport system, according to new research. Cells are exposed to foreign DNA and RNA and it is understood that some of this genetic material can be integrated into the host genome. Using modern microscopic techniques, scientists have been able to see how virus DNA is transported in the cell.
A 22 hours age, baby Toby Dring became Britain's youngest open heart surgery patient. He had Hypoplastic Left Heart Syndrome and had to be given the life-saving operation when his health deteriorated dramatically at birth. Toby's condition affects one in 5,000 babies and occurs when the left side of the heart fails to form properly.
KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.
Wellcome Trust researchers have developed a new form of psychotherapy that has been shown to have the potential to treat more than eight out of ten cases of eating disorders in adults, a study out today reports.
› Verified 4 days ago
Vicki Horn, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 Elizabeth St, Charleston, WV 25311 Phone: 304-348-7740 Fax: 304-348-6671 | |
Rebecca Kelley, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 Elizabeth St, Charleston, WV 25311 Phone: 304-348-7770 | |
Hannah Chinn, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 300 Baker Ln, Charleston, WV 25302 Phone: 304-346-2323 | |
Ericka Brown, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 Elizabeth St, Charleston, WV 25311 Phone: 304-348-7740 Fax: 304-348-6671 | |
Tiffany N Evans, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1026 Gordon Dr, Charleston, WV 25303 Phone: 304-421-0854 | |
Michelle Renee Robinson, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 125 Wertz Ave, Charleston, WV 25311 Phone: 304-610-7171 | |
Ms. Amanda S Casto, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Lincoln Drive, Charleston, WV 25309 Phone: 304-768-4400 |